TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Study Details
Study Description
Brief Summary
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
utilizing HCV-positive donors (defined as HCV-NAT positive) for heart transplantation in HCV-negative recipients treated with Epclusa®.
Subjects will be identified from the heart transplantation waitlist. Subjects who, according to the judgement of the Investigator, would have a net mortality benefit from cardiac transplantation irrespective of donor HCV status will be asked if they agree to receive a heart transplant from an HCV-positive donor. Subjects who sign consent and receive a heart transplant from an HCV-positive donor will be enrolled.
Consented subjects who do not demonstrate immunity to hepatitis B (manifest as negative qualitative or quantitative Hepatitis B surface Ab) will be encouraged to immediately begin a non-infectious recombinant hepatitis B surface antigen vaccination series, combined with, or in parallel to, an inactive hepatitis A vaccination at the treating clinician's discretion.
Enrolled recipients will be closely surveilled with serial HCV polymerase chain reaction (PCR) as inpatients during the immediate post-OHT hospitalization and subsequently as specified in the post-transplant period assessements. Donor serum will be collected at transplant harvest and will be sent by the transplant center for HCV NAT and genotyping. If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course. The study drug, Epclusa®, will be provided by Gilead Sciences, Inc. Study drug, Epclusa®, comes in bottles that contain 28 tablets each. Serologic data will also be collected. If an enrolled subject does not develop quantifiable viremia by week 12, they will be followed by standard of care surveillance, with additional standard of care surveillance per UNOS mandate for CDC-increased-risk donors and discontinued from study; additional subjects may be enrolled at the Principal Consortium Investigator's discretion to complete 20 Epclusa®-treated subjects according to the protocol.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient. |
Drug: Epclusa
If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
|
Outcome Measures
Primary Outcome Measures
- Sustained virologic response after 12 weeks of treatment [12 weeks]
To evaluate the number of patients with sustained virologic response (SVR) 12 weeks after discontinuation of therapy.
Secondary Outcome Measures
- 1-year post-transplant survival [1 year]
To evaluate the number of patients who survive 1-year post-transplant.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Willing and capable of providing written informed consent
-
Age ≥ 18 years
-
Listed for isolated orthotopic heart transplant
-
HCV seronegative (or, if HCV seropositive, then subject must be PCR negative on at least 2 draws consistent with a spontaneously cleared or fully-treated and cleared prior infection; in this case last anti-HCV antiviral dose must be ≥12 weeks ago and 2 negative titers ≥12 weeks after completion of the antiviral regimen)
Exclusion Criteria:
-
Listed for combined organ transplant
-
Any of the following liver disease states, including:
-
History of HCV viremia detectable by either HCV qualitative or quantitative PCR unless deemed cured (SVR-12),
-
Hepatitis B surface Ag positive(unless clinically determined to be previously negative and acutely positive due to vaccination with recombinant surface antigen) or detectable hepatitis B DNA,
-
Cirrhosis, as indicated by liver biopsy,
-
Portal hypertension as indicated by a hepatic venous pressure gradient > 5 mm Hg and/or the presence of esophageal varices e.) ALT and AST > 3x ULN unless adjudicated to be from a non-hepatic cardiac or skeletal muscle source,
-
History of prior solid organ transplant
-
Pregnant individuals
-
History of HIV infection
-
History of severe renal disease currently requiring dialysis. Chronic kidney disease with creatinine clearance <30 ml/min/1.73m2 (by MDRD method) at screening or on last two consecutive measurements before acceptance of transplant organ offer
-
Patients who have undergone or who will undergo immune desensitization therapy
-
Prospective-positive cross-match or predicted positive cross-match
-
Patients unwilling to notify their sexual partner(s) of participation in this trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cedars-Sinai Medical Center | Los Angeles | California | United States | 90048 |
| 2 | Duke University Medical Center | Durham | North Carolina | United States | 27705 |
| 3 | Baylor University Medical Center | Dallas | Texas | United States | 75246 |
Sponsors and Collaborators
- Baylor Research Institute
Investigators
- Study Chair: Shelley A Hall, MD, FACC, FHFSA, Baylor University Medical Center/ Baylor Scott & White Research Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 018-009